Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) insider Milos Miljkovic sold 932 shares of the business's stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $16.72, for a total transaction of $15,583.04. Following the completion of the transaction, the insider now owns 36,341 shares in the company, valued at approximately $607,621.52. The trade was a 2.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Milos Miljkovic also recently made the following trade(s):
Cartesian Therapeutics stock traded down $0.47 during midday trading on Tuesday, reaching $17.16. 105,686 shares of the stock traded hands, compared to its average volume of 132,021. The stock's fifty day moving average is $19.32 and its 200-day moving average is $18.19. Cartesian Therapeutics, Inc. has a 12 month low of $11.66 and a 12 month high of $41.87. The stock has a market cap of $436.12 million, a P/E ratio of -0.32 and a beta of 0.56.
A number of hedge funds have recently added to or reduced their stakes in RNAC. BNP Paribas Financial Markets boosted its stake in shares of Cartesian Therapeutics by 122.5% during the third quarter. BNP Paribas Financial Markets now owns 1,651 shares of the company's stock valued at $27,000 after purchasing an additional 909 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Cartesian Therapeutics during the second quarter worth about $47,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Cartesian Therapeutics during the second quarter valued at $49,000. JPMorgan Chase & Co. lifted its position in Cartesian Therapeutics by 0.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 309,018 shares of the company's stock worth $4,981,000 after acquiring an additional 2,688 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Cartesian Therapeutics by 2.1% in the third quarter. Geode Capital Management LLC now owns 135,700 shares of the company's stock worth $2,188,000 after acquiring an additional 2,737 shares during the period. 86.95% of the stock is currently owned by institutional investors.
Several research firms recently commented on RNAC. HC Wainwright reiterated a "buy" rating and issued a $45.00 target price (up previously from $41.00) on shares of Cartesian Therapeutics in a research report on Wednesday, December 4th. Cantor Fitzgerald upgraded shares of Cartesian Therapeutics to a "hold" rating in a research note on Monday, December 2nd. BTIG Research began coverage on Cartesian Therapeutics in a research note on Thursday, December 19th. They set a "buy" rating and a $42.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $41.00 price objective on shares of Cartesian Therapeutics in a research report on Tuesday, December 3rd. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.86.
Check Out Our Latest Research Report on Cartesian Therapeutics
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cartesian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cartesian Therapeutics wasn't on the list.
While Cartesian Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.